Literature DB >> 15126552

Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development.

Daniela Milani1, John D Carmichael, Joan Welkowitz, Steven Ferris, Richard E Reitz, Ann Danoff, David L Kleinberg.   

Abstract

In recent years, a number of investigators have studied the relationship between IGF-I and risk of developing cancer, diabetes or cardiovascular disease. Upper tertile, quartile, and quintile IGF-Is were associated with higher risk of developing cancer, and lowest quartile with cardiac disease and diabetes. As part of a study to correlate serum IGF-Is and growth hormone dynamics in aging, we measured fasting serum IGF-I at baseline and two weeks later in a group of 84 normal volunteers between the ages of 50 and 90 years. Although the correlation between the two IGF-Is was high (r=0.922; p<0.0001) there were substantial differences between the two IGF-I values ranging from -36.25 to +38.24% between individual IGF-I values at the two blood draws and a significant difference between the mean IGF-Is at visits I and 2 (mean 120.28+/-53.5 vs. 114.95+/-50.03; p=0.03). When considered in quartiles, IGF-I changed from one quartile to another in 34/84 (40.5%) of the volunteers. When the group was divided in halves, tertiles,quartiles, or quintiles there was an increasing number of subjects who changed from one subdivision to another as the number of gradations increased. These results suggest that the predictive outcomes of earlier studies that used single IGF-I samples for analysis of risk ratios according to tertiles, quartiles, or quintiles could have been different if a second IGF-I was used to establish the risk ratio. The results also suggest that variability in IGF-I should be taken into account when designing such studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126552      PMCID: PMC3251209          DOI: 10.1210/jc.2003-032150

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction.

Authors:  N Vaessen; P Heutink; J A Janssen; J C Witteman; L Testers; A Hofman; S W Lamberts; B A Oostra; H A Pols; C M van Duijn
Journal:  Diabetes       Date:  2001-03       Impact factor: 9.461

Review 2.  How should insulin-like growth factor I be measured? A consensus statement.

Authors:  M B Ranke; U Feldt-Rasmussen; P Bang; R C Baxter; C Camacho-Hübner; D R Clemmons; A Juul; H Orskov; C J Strasburger
Journal:  Horm Res       Date:  2001

3.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

Authors:  S M Harman; E J Metter; M R Blackman; P K Landis; H B Carter
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

Review 4.  Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency.

Authors:  D R Clemmons
Journal:  Horm Res       Date:  2001

Review 5.  The insulin-like growth factors.

Authors:  W S Cohick; D R Clemmons
Journal:  Annu Rev Physiol       Date:  1993       Impact factor: 19.318

6.  Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study.

Authors:  D Goodman-Gruen; E Barrett-Connor
Journal:  Am J Epidemiol       Date:  1997-06-01       Impact factor: 4.897

7.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

Authors:  J M Chan; M J Stampfer; E Giovannucci; P H Gann; J Ma; P Wilkinson; C H Hennekens; M Pollak
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

8.  Serum insulin-like growth factor-I and breast cancer.

Authors:  P Toniolo; P F Bruning; A Akhmedkhanov; J M Bonfrer; K L Koenig; A Lukanova; R E Shore; A Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2000-12-01       Impact factor: 7.396

9.  Insulin-like growth factor-I and angiographically documented coronary artery disease.

Authors:  P Spallarossa; C Brunelli; F Minuto; D Caruso; M Battistini; S Caponnetto; R Cordera
Journal:  Am J Cardiol       Date:  1996-01-15       Impact factor: 2.778

10.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  26 in total

Review 1.  Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research.

Authors:  Rachel L Derr; Scott J Cameron; Sherita Hill Golden
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

2.  Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Authors:  Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.

Authors:  Yasuyuki Kinoshita; Atsushi Tominaga; Satoshi Usui; Kazunori Arita; Tetsuhiko Sakoguchi; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  Neurosurg Rev       Date:  2016-01-20       Impact factor: 3.042

4.  Chronic activity-based therapy does not improve body composition, insulin-like growth factor-I, adiponectin, or myostatin in persons with spinal cord injury.

Authors:  Todd A Astorino; Eric T Harness; Kara A Witzke
Journal:  J Spinal Cord Med       Date:  2014-08-17       Impact factor: 1.985

Review 5.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

6.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

7.  Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.

Authors:  G Scirè; C Del Bianco; G L Spadoni; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

8.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

9.  Idiopathic short stature: conundrums of definition and treatment.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2009-03-12

Review 10.  Management of acromegaly in Latin America: expert panel recommendations.

Authors:  Ariel Barkan; Marcello D Bronstein; Oscar D Bruno; Alejandro Cob; Ana Laura Espinosa-de-los-Monteros; Monica R Gadelha; Gloria Garavito; Mirtha Guitelman; Ruth Mangupli; Moisés Mercado; Lesly Portocarrero; Michael Sheppard
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.